During a median follow-up period of @ years , the primary end point occurred in @ of @ patients ( @ % ) in the darapladib group and @ of @ patients ( @ % ) in the placebo group ( hazard ratio in the darapladib group , @ ; @ % confidence interval -LSB- CI -RSB- , @ to @ ; P = @ ) .